Skip to content
value.today
Eton Pharmaceuticals, Inc. logo

Eton Pharmaceuticals, Inc.

🇺🇸 San Diego, California, USAPharmaceuticalsFounded 2017
Total raised
$20 M
1 round on record
Latest round
$20 M
Jun 2017
First round on record
Jun 2017
Today
Went public
See the company page

Eton Pharmaceuticals, Inc. is listed today as Eton Pharmaceuticals, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Eton Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2020$8 MPrivate placement after listing$2 to $10 million

Eton Pharmaceuticals, Inc.: Private sale, Mar 2020

Investors in this round

2 investors had bought by the notice of Apr 8, 2020: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Eton Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Sean Brynjelsen · Executive Officer, Director
  • William Wilson Troutman · Executive Officer
  • Charles J Casamento · Director
  • Mark L Baum · Director
  • Norbert G Riedel · Director
  • Paul V Maier · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by W. Wilson Troutman, CFO, Treasurer & Secretary. Source: SEC Form D, newest notice filed Apr 8, 2020. Read the notice at the SEC.

equitySEC
Jun 2017$20 MNo. 1$10 to $50 million

Eton Pharmaceuticals, Inc.: Raise no. 1, Jun 2017

Investors in this round

230 investors had bought by the notice of Jun 28, 2017: 230 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Eton Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$20 M of $20 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,958,221
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Sean Brynjelsen · Executive Officer, Director
  • Andrew Boll · Director
  • Charles Casamento · Director
  • Mark Baum · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • National Securities Corporation (CRD 7569) · New York, New YorkSold in AR, CA, CO, FL, IL, LA, MD, MI, MN, NJ, NV, NY, PA, TX, VA, WA, WI

Remarks in the notice

  • On fees: “Recipient also received a warrant to purchase up to 652,740 shares of the Issuer's common stock.”

Signed by Sean Brynjelsen, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 28, 2017. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Eton Pharmaceuticals, Inc., its revenue in fiscal 2025 came from these product and service lines: Product Sales and Royalties $76.66 million (96%), License $3.29 million (4%).

    Annual report (SEC XBRL) · Dec 2025

  • Eton Pharmaceuticals, Inc. had revenue of up to $1 million when it filed its newest notice of a funding round (Apr 2020).

    SEC Form D (revenue range) · Apr 2020

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Apr 2020

Products and services#

No products or services of Eton Pharmaceuticals, Inc. are on record.

Investors#

1 named in official filings. Open an investor to see everything it has backed.

Investors in Eton Pharmaceuticals, Inc.
InvestorKindAmountRoundRoleSource
Charles J. CasamentoPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2018)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 230 investors.

Largest shareholders today

Institutions holding Eton Pharmaceuticals, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Eton Pharmaceuticals, Inc.
NameRoleNamed in
Sean BrynjelsenExecutive officerApr 2020
William Wilson TroutmanExecutive officerApr 2020
Charles J CasamentoDirectorApr 2020
Mark L BaumDirectorApr 2020
Norbert G RiedelDirectorApr 2020
Paul V MaierDirectorApr 2020
Sean BrynjelsenDirectorApr 2020
Andrew BollDirectorJun 2017
Charles CasamentoDirectorJun 2017
Mark BaumDirectorJun 2017

Went public since 2018. Its SEC number is that of a company listed on a stock exchange.